We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
APO-NEBIVOLOL, NEBIVOLOL APOTEX (Apotex Pty Ltd)
Product name
APO-NEBIVOLOL, NEBIVOLOL APOTEX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
143 working days (255)
Active ingredients
nebivolol (as hydrochloride)
Registration type
New generic medicine
Indication
APO-NEBIVOLOL, NEBIVOLOL APOTEX (tablets) is indicated for the treatment of:
- essential hypertension;
- stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.